| Immunomodulatory Roles of VIP and PACAP in Models of Multiple Sclerosis. | |
| | |
MedLine Citation:
|
PMID: 21524252 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Multiple sclerosis (MS) is a progressive neurodegenerative disease affecting myelin and axons, which is perpetuated by autoreactive lymphocytes and other inflammatory cell types. Because of the multifactorial nature of this disease, therapies targeting a single process may not be sufficient to halt its progression. VIP and PACAP are two neuropeptides shown to regulate multiple aspects of innate and adaptive immunity, and can also act independently on neural cells to promote their survival and regeneration. Animal studies have proven the efficacy of these peptides for the treatment of several models of neural inflammatory disorders, including those which, like MS, have major Th1/Th17 components. In this review, the immunomodulatory actions of VIP and PACAP will be discussed, with particular emphasis on their potential significance in MS. |
| | |
Authors:
|
Catalina Abad; James A Waschek |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-3-18 |
Journal Detail:
|
Title: Current pharmaceutical design Volume: - ISSN: 1873-4286 ISO Abbreviation: - Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-4-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9602487 Medline TA: Curr Pharm Des Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: VIP-Induced Neuroprotection of the Developing Brain.
Next Document: Strategies to Convert PACAP from a Hypophysiotropic Neurohormone into a Neuroprotective Drug.